Investment Rating - The investment rating for JD Health (6618.HK) is "Buy" [1] Core Insights - The company reported a revenue of 73.441 billion yuan for 2025, representing a year-on-year growth of 26.28%. The pre-tax profit was 6.03 billion yuan, up 25.7%, and the net profit attributable to shareholders was 5.367 billion yuan, reflecting a 29.1% increase. The non-IFRS profit was 6.533 billion yuan, showing a growth of 36.3% [2][3] - The growth in revenue is driven by an increase in active users, category expansion, and improved penetration rates. The number of active users reached 218 million in 2025, a year-on-year increase of approximately 19% [3] - The company has strengthened its position as the "first station for the launch of new drugs online," with over 100 new drugs launched in 2025, compared to over 30 in 2024 [3] - The AI healthcare services have been expanded, providing comprehensive health management services, including an AI doctor that has completed hundreds of millions of interactions with a 98% satisfaction rate [3][4] Financial Summary - For 2026, the projected revenue is approximately 87.602 billion yuan, with a year-on-year growth rate of 19%. The net profit is expected to be around 5.437 billion yuan, with a growth rate of 1% [5][6] - The gross margin is projected to improve to 25.57% in 2026, with a net profit margin of 8.9% [5][6] - The earnings per share (EPS) for 2026 is estimated at 1.69 yuan, with a price-to-earnings (P/E) ratio of 25.15 [5][6]